|
EP3773717A1
|
|
Treatment of autoimmune and inflammatory disorders using antibodies that bind interleukin-17a (il-17a)
|
|
EP3755327A1
|
|
Calcitonin gene-related peptide (cgrp) antagonist antibodies
|
|
WO2019028182A2
|
|
Cancer treatment using antibodies that bind human cd134 (ox40) receptor
|
|
EP3585430A1
|
|
Cancer treatment using antibodies that bind cytotoxic t-lymphocyte antigen-4 (ctla-4)
|
|
CN110366564A
|
|
Use the immunotherapy of the antibody combined with programmed death 1 (PD-1)
|
|
WO2018119475A1
|
|
Immunotherapy using antibodies that bind programmed death ligand-1 (pd-l1)
|
|
CA3036273A1
|
|
Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
|
|
US2019002577A1
|
|
Methods Of Treating Type 2 Diabetes Mellitus Using Glucagon Receptor Antagonistic Antibodies
|
|
WO2017062693A1
|
|
Methods for treating rare genetic disorders using glucagon receptor antagonistic antibodies
|
|
US2017143673A1
|
|
Methods For Treating Heart Failure Using Glucagon Receptor Antagonists
|
|
US2018256713A1
|
|
Methods for treating heart failure using glucagon receptor antagonistic antibodies
|
|
AU2016242935A1
|
|
Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor antagonistic antibodies
|
|
EP3151855A2
|
|
Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
|
